Skip NavigationSkip to Content
Return Return to Search Results

PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies

  1. Author:
    Bavli, Yaelle
    Chen, Bing-Mae
    Roffler, Steve R
    Dobrovolskaia,Marina
    Elnekave, Eldad
    Ash, Shifra
    Barenholz, Yechezkel
    Turjeman, Keren

  2. Author Address

    Laboratory of Membrane and Liposome Research, Department of Biochemistry, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem 9112102, Israel., Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan., Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA., Davidoff Cancer Institute, Rabin Medical Center, Petach Tikva 4941492, Israel., Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children 39;s Medical Center of Israel, Petach Tiqva, Tel Aviv University, Tel Aviv 4920235, Israel.,
    1. Year: 2020
    2. Date: Jan 28
    3. Epub Date: 2020 01 28
  2. Journal: Molecules (Basel, Switzerland)
    1. 25
    2. 3
    3. Pages: pii: molecules25030558
  4. Type of Article: Article
  5. Article Number: 558
  6. ISSN: 1420-3049
  1. Abstract:

    PEGylated nanomedicines are known to induce infusion reactions (IRs) that in some cases can be life-threatening. Herein, we report a case study in which a patient with rare mediastinal and intracardiac IgG4-related sclerosing disease received 8 treatments of intravenously administered PEGylated liposomal methylprednisolone-succinate (NSSL-MPS). Due to the ethical requirements to reduce IRs, the patient received a cocktail of premedication including low dose of steroids, acetaminophen and H2 blockers before each infusion. The treatment was well-tolerated in that IRs, complement activation, anti-PEG antibodies and accelerated blood clearance of the PEGylated drug were not detected. Prior to the clinical study, an in vitro panel of assays utilizing blood of healthy donors was used to determine the potential of a PEGylated drug to activate complement system, elicit pro-inflammatory cytokines, damage erythrocytes and affect various components of the blood coagulation system. The overall findings of the in vitro panel were negative and correlated with the results observed in the clinical phase.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/molecules25030558
  3. PMID: 32012928
  4. View record in Web of Science®
  5. WOS: 000515384800128
  6. PII : molecules25030558

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel